Abstract 5371: Immune correlates of survival in advanced hepatocellular carcinoma patients treated with glypican-3-derived peptide vaccine: Results from phase I trial
Yu Sawada(Shizuoka Cancer Center), Tetsuya Nakatsura(Unknown), Toshiaki Yoshikawa(Aichi Cancer Center), Manami Shimomura(National Cancer Center Hospital East), Keigo Saito, Daisuke Nobuoka(Fukuyama City Hospital), Shoichi Mizuno(Shizuoka Cancer Center)
Cited by 0
Related Papers
Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
|Clinical Cancer Research|2012|304
Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
|OncoImmunology|2016|178
Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy
|Cell stem cell|2018|163
Risk factors for major morbidity after liver resection for hepatocellular carcinoma
|British journal of surgery|2012|104